Schrodinger Quarterly Cash Flow Statement
NASDAQ: SDGRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
27.28+0.89 (+3.37%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Schrodinger free cash flow
In the quarter ended Jun 30, 2026, Schrodinger generated -$34.1 million of operating cash flow and spent $362,000 on capital expenditures. That left free cash flow of -$34.4 million, a free-cash-flow margin of -58.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Schrodinger cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 5.97M | -60.03M | 32.51M | -32.80M | -43.17M | -59.81M | -40.22M | -38.14M | -54.05M | -54.72M | -30.67M | -62.02M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | -1363.37% | -142.38% | — | — |
| Depreciation & Amortization | 1.49M | 1.48M | 1.44M | 1.47M | 1.53M | 1.59M | 1.76M | 1.56M | 1.40M | 1.44M | 1.35M | 1.27M |
| Stock-Based Compensation | 8.79M | 9.07M | 9.95M | 10.85M | 10.63M | 11.57M | 12.48M | 12.40M | 12.81M | 12.22M | 12.53M | 12.65M |
| Change in Working Capital | -9.85M | 31.13M | -32.94M | -30.34M | -19.73M | 205.10M | -47.47M | 1.97M | -6.99M | 28.68M | -25.09M | -18.20M |
| Operating Cash Flow | -34.07M | -14.83M | -16.09M | -61.87M | -52.20M | 144.06M | -31.11M | -33.26M | -53.72M | -39.28M | -37.26M | -49.94M |
| Capital Expenditures | -362.00K | -2.51M | -41.00K | -491.00K | -314.00K | -596.00K | -873.00K | -1.34M | -1.00M | -4.09M | -2.48M | -4.92M |
| Investing Cash Flow | 58.62M | 44.60M | 71.41M | 11.46M | -55.60M | 30.63M | 23.48M | 90.70M | 29.58M | 5.08M | -59.61M | 13.20M |
| Financing Cash Flow | 650.00K | 569.00K | 197.00K | 307.00K | 2.02M | 409.00K | 119.00K | 392.00K | 1.61M | 8.01M | 2.33M | 1.33M |
| Net Change in Cash | 25.20M | 30.33M | — | -50.11M | -105.78M | 175.10M | — | 57.84M | -22.54M | -26.19M | — | -35.41M |
| Free Cash Flow | -34.43M | -17.34M | -16.13M | -62.36M | -52.51M | 143.47M | -31.99M | -34.60M | -54.72M | -43.37M | -39.73M | -54.86M |
This table shows 12 quarterly periods of Schrodinger's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SDGR's reporting calendar. What is a cash flow statement?